In vitro transformation of primary cultures of chick embryo ®broblasts by the membrane-bound vSrc or the nuclear vJun oncoproteins is correlated with a downregulation of the secreted glycoprotein SPARC (also called BM-40 or osteonectin). This protein is a nonstructural component of the extracellular matrix that is thought to regulate cell ± matrix interaction during development, wound repair, and carcinogenesis. Its precise function remains unclear. To estimate the contribution of SPARC down-regulation to the major aspects of the transformed phenotype, we have reexpressed this protein from a self-replicating retrovirus Rcas, designated R-SPARC, in the transformed cultures. These R-SPARC-infected cultures display the following main properties: (i) they accumulate the SPARC protein to a level identical to or only slightly higher than the level in normal chick embryo ®broblasts; (ii) they retain the main phenotypic properties characteristic of in vitro transformed cells, that is, altered morphology, capacity to grow in a reduced amount of serum, and capacity to develop colonies from single cells in agar; (iii) they display a clearly reduced capacity to develop local ®brosarcomas in vivo. Taken together, these data strongly suggest that down-regulation of SPARC contributes to the transformed phenotype triggered by vSrc and vJun in primary avian ®broblasts, by facilitating in vivo tumorigenesis.
Introduction
Transformation of chick embryo ®broblasts (CEFs) as induced by the membrane-associated vSrc oncoprotein from Rous sarcoma virus, results in the acquisition of four major, abnormal phenotypic properties: (i) an alteration in cell morphology; (ii) a reduced serum requirement for proliferation; (iii) an anchorage-independent growth capacity; and (iv) in vivo tumorigenicity. Numerous reports in this avian model have associated transformation with complex changes in gene expression, aecting among other aspects the composition and organization of the cytoskeleton and the extracellular matrix (Jove and Hanafusa, 1987) .
Transcription factor AP1 is a nuclear target of the vSrc-induced oncogenic pathway (Muramaki et al., 1997; Suzuki et al., 1994) and is thought to trigger part of the phenotypic spectrum induced by vSrc (Bos et al., 1990; Castellazzi et al., 1990; Muramaki et al., 1997; Suzuki et al., 1994; van Dam et al., 1998) . This transcription factor consists of a collection of homo-and heterodimers between members of the Jun, Fos and ATF/CREB family (Karin et al., 1997) . The vJun oncoprotein, a mutated version of cellular cJun, initially isolated from retrovirus ASV17 (Maki et al., 1987) , is thought to transform by promoting aberrant transcription of oncogenically relevant target genes (Vogt, 1994) .
In the search for such target genes whose activity is modulated in vSrc-and/or vJun-transformed CEFs, we became interested in a particular component of the extracellular matrix, called SPARC for secreted protein, acidic and rich in cysteine (Mason et al., 1986a,b) . This protein was initially designated as osteonectin (Termine et al., 1981) and later as BM-40 for basement membrane-40 (Dziadek et al., 1986; reviewed in Reed and Sage, 1996; Timpl and Aumailley, 1993) . SPARC displays a high degree of sequence conservation from Caenorhabditis elegans to humans, indicating a basic functional role in animal tissues (Lankat-Buttgereit et al., 1998) . Although SPARC level is highest in bone and in basement membranes, it is also expressed in a variety of cell types and associated with remodelling tissues and sites of high cellular turn-over. In vitro studies with SPARC peptides (Funk and Sage, 1993) and with primary cultures from SPARC null mice (Bradshaw et al., 1999) indicate that this protein regulates cell proliferation. SPARC has been shown to be repressed by cJun in rat embryo ®broblasts at the mRNA and protein level (Mettouchi et al., 1994) and by vSrc in CEFs at the mRNA level (Young et al., 1986) , suggesting a role for this protein in cell transformation.
In the present study, we asked whether SPARC down-regulation contributes to the transformed phenotype established by vSrc or vJun in primary avian cells. Therefore CEFs stably transformed by these oncoproteins were generated. After having shown that SPARC was indeed repressed in these cultures, we analysed the consequence of its reexpression with respect to the major oncogenic properties induced by these oncoproteins.
Results
Steady-state level of SPARC mRNA and protein in CEFs stably transformed by vSrc and vJun Uninfected CEFs or CEF cultures chronically infected by R, R-vSrc, R-vJun, or R-vJun-m1 (a mutant of vJun that exhibits enhanced tumorigenicity in vivo; Huguier et al., 1998) were generated. Total RNA was subjected to Northern blot analysis with an avian SPARC radioactive probe (Figure 1 ). The level of SPARC mRNA was estimated in the transformed CEFs in comparison with the non-transformed CEFs (referred to as 100%). A reduction of 50% was found with R-vJun, and of 80% with R-vSrc. The strongest reduction (over 90%) was observed with R-vJun-m1. Reprobing of the same blot with GAPDH cDNA indicated the same loading for the dierent lanes.
Protein extracts from the same cultures were subjected to Western blot analysis followed by immunodetection of the SPARC protein. As expected from the mRNA levels, SPARC accumulation was reduced in the transformed CEFs (Figure 3a) . With non-transformed CEFs arbitrarily set at 100%, vSrcand vJun-m1-transformed CEFs showed almost undetectable SPARC levels, i.e. 510% and 55%, respectively. These data show that transformation of CEFs by either vJun or vSrc is accompanied by a clearcut reduction in the accumulation of the SPARC mRNA and protein.
Re-expression of SPARC in vSrc-and vJun-transformed CEFs
An Rcas envD derivative carrying the entire coding sequence of SPARC with the N-terminal peptide signal, designated RD-SPARC, was constructed ( Figure 2 ). CEFs infected by RD or RD-SPARC were generated and superinfected with R, R-vJun, RvJun-m1, or R-vSrc. Protein cell extracts were subjected to Western blot analysis and probed successively with antibodies speci®c to SPARC, Jun, and Src. As shown in Figure 3a (upper panel), infection with RD-SPARC correlated with an enhanced accumulation of the SPARC protein in all cultures, reaching a level identical to, or slightly (about twofold) higher than the level in normal CEFs. By short exposure (Figure 3a lower panel), SPARC could be resolved into two distinct, closely-migrating bands. Although the relative intensity of these bands varied from one extract to another, the upper band was usually more intense. Both bands seemed to correspond to the mature form of SPARC, devoid of the peptide signal (see right lane`in vitro translated' SPARC sig + and SPARC sig 7 for comparison). As shown in Figure 3b , a treatment of the extracts with N-glycosidase shifted the slower-migrating upper band to a single, fast-migrating band. The two closelymigrating bands are therefore likely to correspond to two isoforms of mature SPARC with distinct glycosylation levels. This explanation is consistent with the existence of potential N-linked glycosylation sites at Asn 67 and Lys 95 in the avian protein (Bassuk et al., 1993) .
Detection of the SPARC protein was also performed at the single cell level by immuno¯uorescence. In agreement with previous reports (Mettouchi et al., 1994; Reed and Sage, 1996) , SPARC could be detected intracellularly in the cytoplasm. The staining was homogeneously distributed within the cell population. As expected, SPARC accumulation was strongly reduced in m1-and Src-transformed CEFs, and returned to a wild-type level as a consequence of RD-SPARC superinfection (data not shown).
In the Jun-transformed CEFs (Figure 3c , upper panel), accumulation of the vJun and vJun-m1 oncoproteins was clearly detected, reaching about ®vefold the level of the endogenous cJun. There was no signi®cant dierence in the presence or absence of exogenous SPARC. In the vSrc-transformed CEFs (Figure 3c , lower panel), a strong accumulation of the oncoprotein was observed, reaching over 20-fold the level of the endogenous cSrc. Again, there was no signi®cant dierence with or without exogenous SPARC. In these vSrc-transformed cells endogenous cJun accumulated as a consequence of the activation of AP1 by vSrc (Suzuki et al., 1994) .
Taken together, these data show that SPARC can be eciently re-expressed in the RD-SPARC-infected, transformed CEFs, and accumulates to levels identical Effect of SPARC re-expression on Jun-and Src-mediated transformed phenotype in vitro RD-SPARC did not signi®cantly alter the morphology of either non-transformed or transformed CEFs. vJunand vSrc-transformed cells displayed a typical fusiform (Bos et al., 1990; Maki et al., 1987) or slightly rounded and refractile morphology (Jove and Hanafusa, 1987; Mayer et al., 1986) , regardless of their SPARC content. Moreover RD-SPARC did not aect the main growth , respectively in the absence of SPARC ( Figure  4b ). A small enhancement of plating eciency with SPARC was also observed for CEFs transformed by vJun, vJun-m1, and vSrc when plated as single cells in agar (by a 1.1-, 1.3-, and 2.3-fold factor, respectively) ( Table 1) . RD-SPARC could not in itself induce growth in low-serum ( Figure 4b , left) or colony formation in agar (Table 1) in the non-transformed cultures.
These results were unexpected. They showed that, although RD-SPARC cannot transform CEFs, this virus stimulates the transforming activity mediated by vJun(-m1) or vSrc, with respect to proliferation in low serum and in agar. Thus, down-regulation of SPARC is not needed for in vitro transformation by Jun and Src; on the contrary, excess SPARC even constitutes a stimulatory factor in this oncogenic process.
Effect of SPARC re-expression on Jun-and Src-mediated tumorigenesis in vivo
In a ®rst series of experiments, the development of local, primary ®brosarcomas was tested by injecting CEFs stably transformed by vJun-m1 (2610 6 cells per animal), into the wing web of 1-day-old chicks. vJunm1 was chosen instead of vJun because this mutant is a Figure 4 Growth curves of CEF cultures chronically infected by the empty Rcas vector, or by Rcas vectors expressing vJun, vJunm1, or vSrc with or without SPARC. Cultures were grown either in normal medium (supplemented with 6% serum; (a)) or in medium with reduced amount of serum (0.6%; (b)). Cell numbers correspond to the mean for two 100 mm petri dishes (2610 6 and 0.5610 6 for m1-and Src-transformed CEFs, respectively) were injected subcutaneously into the wing web of 1-day-old chicks. Data represent tumor size after a given number of weeks as indicated. In a chicks no. 7, 8, 9 and 10 did not develop any visible tumors and were sacri®ced after 6 weeks more potent tumor-inducer . The formation of tumors was monitored over a 6-week period. As shown in Figure 5a , vJun-m1-transformed CEFs induced tumors in all birds, i.e. in ®ve birds out of ®ve injected. Strikingly, exogenous SPARC strongly reduced the number of tumors, since only one bird (no. 6) out of ®ve developed a tumor. Furthermore this tumor developed late, between weeks 5 and 6. Birds injected with RD-SPARC-infected CEFs, i.e. without Jun or Src, did not develop any tumor at all (data not shown). A histopathological analysis of the m1 and the m1+SPARC tumors was performed. These tumors were identically diagnosed as low-grade, highly cellular typical ®brosarcomas. In contrast to the m1 tumors whose cellular compartment was largely disseminated within a very abundant matrix, the m1+SPARC tumor showed a more condensed, well delimited cellular compartment, with a reduced amount of extracellular matrix (Figure 6) .
In a second series of experiments (Figure 5b ), tumor development was tested by injecting vSrc-transformed CEFs with or without compensatory SPARC reexpression. Tumorigenesis was more ecient with vSrc compared to vJun-m1 in that: (i) less cells were needed per animal for 100% tumor induction (i.e. 0.5610 6 cells rather than 2610 6 cells); and that (ii) the period of latency was clearly shorter. Therefore these experiments were conducted over a 3-week period. The presence of re-expressed SPARC had a clear-cut inhibitory eect on tumor growth because: (i) not all animals (e.g. only 11 out of 12) developed a tumor; and (ii) the rate of development and the ®nal size of the tumors were signi®cantly reduced. The average size with vSrc+SPARC was only one-third the size reached by vSrc-induced tumors after the 3 weeks. Even with such a powerful oncoprotein, SPARC displayed an anti-tumoral eect, essentially by reducing the rate of tumor development. Histological analysis of the vSrc and vSrc+SPARC tumors did not reveal any clear dierence between them. All were diagnosed as aggressive ®brosarcomas with a high mitotic index, regions of necrosis and a poor collagen matrix ( Figure  6 ).
The steady-state level of the SPARC, Jun, and Src proteins was analysed in cell lines expanded in vitro from several tumors and compared to the original cultures before injection (Figure 7) . The tumor-derived cell lines (noted T) were numbered according to the chick numbers in Figure 5a ,b. Western blotting followed by immunodetection gave the following results: (i) The level of SPARC was clearly reduced in ®ve out of six tumor-derived cultures (compare T2 with m1; T6 with m1+SPARC; T5 and T4 with vSrc; and T13 with Src+SPARC; only T17 exhibited a high level of SPARC identical to the original culture). This reduction was also observed in cultures in which SPARC had not been re-expressed (i.e. T2, T5 and T4); (ii) vJun accumulated at the same level in the original cultures transformed by vJun-m1 +/7 SPARC and in tumor derived cultures (T2 and T6). An additional high molecular weight product of about 70 kDa was observed in culture T6 that might correspond to a Gag ± Jun fusion product; such fusion events have already been described in this particular test (Morgan et al., 1994) and have been shown to generate a more potent vJun oncoprotein; the presence of such a Jun mutant might have contributed to the development of the unique tumor in chick no. 6 that arose from a culture co-expressing m1 and SPARC; and ®nally (iii) the level of vSrc was the same in all cultures in which this oncoprotein had been introduced.
Taken together, the data showed that re-expression of SPARC in vJun-m1 and vSrc-transformed CEFs antagonizes tumorigenesis induced by these oncoproteins, and consequently, that down-regulation of SPARC facilitates in vivo tumorigenesis. This view is reinforced by the recovery of ®ve out of six tumor lines that exhibit reduced level of SPARC (including cell lines in which de novo SPARC had not been reexpressed).
Discussion
In this paper we have con®rmed a previous report (Young et al., 1986) showing strong down-regulation of SPARC mRNA in vSrc-transformed CEFs (480% reduction). We have further shown that such a downregulation also takes place in vJun-transformed CEFs (40 ± 60% reduction) and, to an even greater extent, in CEFs transformed by vJun-m1 (480% reduction), a highly tumorigenic mutant of vJun . This down-regulation parallels a similar reduction in the accumulation of the SPARC protein in the transformed cultures.
The reduction of SPARC expression is not restricted to transformation by vSrc and vJun in primary avian cells. We have shown that CEFs transformed by RRas, an Rcas derivative that expresses an activated form of the avian cRas (mutant ras 12 glu; Givol et al., 1992) also down-regulates SPARC to a level identical to R-vSrc (data not shown). Recently strong repression of SPARC mRNA has also been found in quail embryo ®broblasts transformed by vMyc (Oberst et al., 1999) . In mammalian cells, independent reports also show repression of SPARC mRNA and protein in primary rat embryo ®broblasts which transiently express cJun (Mettouchi et al., 1994) as well as in immortalized rodent ®broblasts stably transformed by cJun, Ha-ras (Mettouchi et al., 1994) , vAbl, vSrc (Mason et al., 1986a,b) , and Ki-Ras (Colombo et al., 1991) . In contrast, the simian virus 40 and bovine papilloma virus 1 oncogenes exert little or no repressive eect on SPARC (Colombo et al., 1991; Kraemer et al., 1999) . Together these data strongly suggest a functional link between the transformed state as established in cultured cells by certain oncoproteins and the down-regulation of SPARC. To further test this hypothesis we have introduced an exogenous SPARC gene from a retrovirus in the vSrc-and vJun-transformed CEFs, looking for a possible reversion of the transformed phenotype.
De novo SPARC does not signi®cantly alter the morphology of either non-transformed CEFs or CEFs transformed by vSrc and vJun. The absence of a morphological response to SPARC re-expression in stably transfected clones from two human cell lines otherwise de®cient in endogenous SPARC has already been reported (Nischt et al., 1991) . In contrast, stably transfected teratocarcinoma F9 stem cells overexpressing SPARC became permanently aggregated and Figure 5a and b. Cell extracts from m1, m1+SPARC, vSrc, and vSrc+SPARC were those from the original CEF cultures before inoculation, and are independently presented in Figure 3 . Western blotting was followed by detection of the accumulated proteins with speci®c antibody using the ECL detection system Anti-tumoral effect of SPARC in chickens E Vial and M Castellazzi rounded (Everitt and Sage, 1992) . Discrepancies between these results might re¯ect cell-type speci®cities, medium conditions, and/or dierences in the level of exogenous SPARC accumulation. Re-expression of SPARC does not prevent growth in low serum and colony formation in agar. On the contrary, exogenous SPARC enhances the growth capacity of transformed cultures, without aecting the non-transformed cultures. It has recently been suggested that SPARC might participate in the recruitment of growth factors to the cell surface, and thus modulate cell proliferation; for example the plateletderived growth factor may bind within the follistatinlike structure of SPARC (Hohenester et al., 1997) . It is therefore possible that SPARC stimulates proliferation in agar and in low serum by facilitating the interaction between certain growth factors and their surface receptors. Such a mechanism might contribute to carcinogenesis, for example during late stages of cancer progression with tumor cells expressing high amounts of SPARC.
Re-expression of SPARC antagonizes tumorigenesis induced by vSrc and vJun and most cell lines derived from tumors display a reduced accumulation of the SPARC protein. Excess SPARC might act by inhibiting neovascularization of the growing tumor. This is an attractive hypothesis because SPARC has recently been shown to directly interact with, and inhibit the mitogenic eect of vascular endothelial growth factor (Kupprion et al., 1998) , a downstream target of Jun (Kraemer et al., 1999) and Src (Mukhopadhyay et al., 1995) . Although no change in the vascularization of the tumors was evident (data not shown), a detailed histological analysis at early stages of tumor development would allow this to be resolved. The reduced level of SPARC protein in tumor-derived cultures might have resulted from the in vivo selection of a subpopulation of injected CEFs that harbor a reduced number of RD-SPARC proviruses, and/or from host ®broblast cells that were secondarily infected by RvJun or R-vSrc, and not by RD-SPARC. Whatever the exact reason is, it is nevertheless clear that a low level of SPARC favors tumor development, at least in this particular test used, that is, the induction of local, primary ®brosarcomas after subcutaneous injection of Src-or Jun-transformed CEFs. In this test there are no secondary, internal metastatic foci visible, and no animal death within the 2 months after inoculation; sometimes tumors even cease to grow and regress. High levels of SPARC have repeatedly been reported to be associated with neoplastic progression of breast (Bellahcene and Castronovo, 1995) and colon cancer (Porte et al., 1995) , and to correlate with later, more aggressive stages of melanoma (Ledda et al., 1997) in humans. It is tempting to speculate that a secondary enhancement of SPARC levels in the cancer cells might help the dissemination of these primary tumors, and that SPARC down-regulation and up-regulation might contribute to distinct stages in carcinogenesis. In line with this speculation, we have recently obtained some evidence that SPARC can be up-and down-regulated by distinct vJun-containing, AP1 heterodimers (Vial and Castellazzi; to be published). Moreover a biphasic regulation has been reported during transformation of rat ®broblasts, both for the cJun-controlled tenascin-C (Mettouchi et al., 1997) and for the vSrc-controlled thrombospondin-1 (Slack and Bornstein, 1994) . These two extracellular proteins, like SPARC, are thought to regulate cell-matrix interaction (Sage and Bornstein, 1991) .
Finally, the re-expression of SPARC induces a reversion of the transformed phenotype that is only partial, and restricted to the situation in vivo. It is likely that other components of the extracellular matrix contribute to a more complete restoration of a normal phenotype. Many genes coding for such components are known to be repressed by vSrc in CEFs. As shown in Figure 8 , some of these genes are simultaneously repressed by vJun and/or by m1 (e.g. ®bronectin, thrombospondin 2, a2 (I) collagen, and collagen XII), others are speci®cally repressed by vSrc (e.g. a1 (I) collagen and lysyl oxidase) or by vJun (e.g. clusterin and decorin). Some of these genes have already been shown to individually exhibit transformation-suppressing activity when stably re-expressed in malignant tumor cells of mammalian origin (e.g. ®bronectin; (Akamatsu et al., 1996) ; decorin (Santra et al., 1995) ; thrombospondin (Sheibani and Frazier, 1995) ; a2 (I) collagen (Travers et al., 1996) ). It would therefore be worthwhile to re-express these genes in our transformed CEFs, alone and in combination with SPARC, in an attempt to reveal a functional cooperation between these extracellular matrix components in relation to oncogenesis. 
Materials and methods

DNA constructs
The cDNA sequence encoding the secreted form of the avian SPARC, noted rSPARC, has been recovered from the original plasmid rSPARC-pCR II (Bassuk et al., 1993) as a 928 base pair, EcoRI ± EcoRI fragment, and inserted at EcoRI into the pH plasmid to generated pH-rSPARC. pH is a pBluescript II SK + derivative (Stratagene) in which the SacI to SalI fragment from the original polylinker has been modi®ed (Baguet and Castellazzi; unpublished data); the new polylinker contains the following primer/promoter sequences, restriction sites, and polyA sequence in the order: RP ± BssHII ± T3 ± SP6 ± ClaI ± HindIII ± PstI ± SalI/ AccI ± XbaI ± BamHI ± SmaI ± SacI ± EcoRI ± ClaI-polyA 30 ± NotI ± XhoI ± ApaI ± KpnI ± T7 ± BssHII ± M13. This pH plasmid is used for DNA sequencing, in vitro protein synthesis, and as an adaptor plasmid replacing the CLA12 plasmids (Hugues et al., 1987) for introduction of the coding sequences as a ClaI ± ClaI fragment into the replication competent, retroviral vector Rcas at the unique ClaI site (Hugues et al., 1987) .
A pH-rSPARC derivative was constructed that contains the natural peptide signal sequence (Met 717 to Ala 71; see Figure 1 in Bassuk et al., 1993) in front of Ala+1 from the rSPARC sequence and designated pH-SPARC sig+. To do this, two double-stranded, synthetic oligonucleotides linked together by means of an arti®cial S®I site have been inserted into pH-rSPARC open at the restriction sites HindIII from the pH polylinker and BglII from the coding sequence (covering amino acids Glu+14 to Leu+16). The sequence of the HindIII ± BglII coding strand is the following: 5'-AAGCTTGCTGCAAG ATG AGA ACC TGG ATT TTC TTC TTC CTC TGC CT G GCC GCC AA G GCC CTG GCA GCT CCG CAA GAG GCT CTG GCT GAT GAG ACG GAG GTG ATT GAA GAT CT. Underlined codons ATG, GCA, GCT and GAT encode Met717, Ala71, Ala+1, and Leu+16, respectively. The arti®cial site S®I does not modify the amino acid sequence of the peptide signal and is shown in italics. A pH-SPARC derivative was also constructed that encodes the secreted form, devoid of the peptide signal, designated pH-SPARC sig7, with a BamHI site in front of the ATG. To do this, a PCR product was cloned into pH-rSPARC open at the restriction sites BamHI from the polylinker and SphI from the coding sequence (covering amino acids Arg+144 to Arg+146). PCR sense and anti-sense primers were 5'-CTGCTCAGA GGA TCC GGT ATG GCT CCG CAA GAG GC and 5'-GCA CAT TCT TCA GCC AGT CCC GCA TGC GCA GG respectively. Restriction sites for cloning are underlined. pH-SPARC sig7 was used for in-frame cloning of the secreted form as a BamHI ± EcoRI fragment into pGEX-2T (Pharmacia) to generate a glutathione S-transferase (GST)-SPARC sig7 fusion protein for antibody production. The vJun coding sequence was introduced in-frame into pGEX-2T as a BamHI ± EcoRI for antibody production. In all cases changes in the pH derivatives were con®rmed by DNA sequencing.
The vSrc ts72 coding sequence was recovered as a 1674 base pair, NcoI ± NruI fragment from the pXD72 plasmid (Mayer et al., 1986) , inserted into the CLA12 NCO adaptor plasmid (Hugues et al., 1987) between NcoI and SmaI, to generate CLA12 NCO vSrc ts72 for subsequent cloning into Rcas. Rcas envA viruses expressing vJun and vJun-m1 have already been described van Dam et al., 1998 ). An Rcas envD virus expressing SPARC sig+ was also generated.
Cell culture
Primary CEF cultures were prepared from 8-day-old C/E SPAFAS chicken embryos (Merial, Lyon, France) and grown in normal medium supplemented with 6% serum as described (Castellazzi et al., 1990) . vJun-, vSrc-, and SPARC-expressing cultures were obtained by chronic infection with the replication-competent retrovirus Rcas (Hugues et al., 1987) . Co-infections were performed with Rcas vectors with two dierent envelope speci®cities, envA and envD, and designated R and RD respectively. Routinely, transfections with RD (no insert) and RD-SPARC, R-vJun, R-vJun-m1, R-vSrc ts72 plasmid DNAs were performed after the ®rst passage using the DMSOpolybrene technique (Kawai and Nishizawa, 1984) , and viruses were allowed to spread through the entire population over the following week. Doubly infected cultures were then generated by superinfection of RD-derivatives with culture supernatant from CEFs chronically infected by R-derivatives, and allowed to grow for another week. Colony formation in agar and growth in low serum medium were performed as described (Castellazzi et al., 1990) . To generate cultures from tumor cells, tumoral tissues were sliced into small pieces and incubated overnight in regular medium supplemented with collagenase H (1 mg/ml ®nal concentration, Boehringer). Cells were subsequently passaged in medium routinely used to grow CEFs.
Antibodies and Western blotting
A GST-SPARC fusion protein was prepared from bacteria carrying the pGEX-2T SPARC sig7 plasmid as described in the`GST-gene fusion' kit (Pharmacia). Rabbits were immunized by repeated intradermal injection of the puri®ed protein following standard technique (Covalab, Lyon, France). Preparation of cell extracts for Western blotting were performed as described (Castellazzi et al., 1990) . For Western blotting, 10 mg protein from total cell extract was resolved by SDS/10%-polyacrylamide gel electrophoresis (PAGE) and blotted onto nitrocellulose membranes that were further incubated with speci®c anti-SPARC antibody. The peroxidase-coupled secondary anti-rabbit antibody was purchased from Amersham (ECL detection system).
For enzymatic removal of SPARC N-linked carbohydrates, N-glycosidase F (1.5 units; Roche) was added to denatured protein extracts (10 mg) in 10 ml of 100 mM Na 2 HPO 4 /NaH 2 PO 4 pH 8, 30 mM EDTA, 1% Triton X-100, 1.5% SDS, 10 mM O-phenanthroline, 1% b-mercaptoethanol and incubated overnight at 378C. Samples without enzyme were treated identically to samples containing N-glycosidase F. The oligosaccharide removal was assessed by SDS ± PAGE.
Commercial mouse monoclonal anti-SPARC and anti-Src were purchased from Haematologic Technologies Inc. (Essex, VT, USA; cat no. AON-5031), and from Upstate Biotechnology (Lake Placid, USA; cat no. 05-185), respectively. Rabbit anti-Jun antibody that recognize both avian cJun and vJun were generated against a GST-vJun fusion protein (Baguet and Castellazzi; unpublished data).
Northern blotting
Total RNA was extracted essentially according to a published procedure (Piu et al., 1993) . Brie¯y, exponentially growing cells were lysed in GET solution (5 M guanidium isothyocyanate, 50 mM Tris pH 7.5, 10 mM EDTA pH 8, 0.1 mM b mercaptoethanol), then precipitated overnight at 08C after addition of eight volumes of LiCl 4 M. After centrifugation for 1 h at 48C , the pellet was resuspended in TESP solution (10 mM Tris pH 7.5, 1 mM EDTA pH 8, 0.1% SDS, 5% phenol), phenol/chlorophorm extracted twice, then ethanol precipitated, and ®nally resuspended in 10 mM Tris pH 8, 10 mM EDTA, 1% SDS. Northern blot analysis was performed using conventional methods. Radioactive probes were coding sequences of avian SPARC and glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH).
Histological study
Tumors were ®xed in Bouin's solution and embedded in paran. Consecutive 4 mm-thick sections were cut. Evaluation of in¯ammation, necrosis, and ®brosis was performed using a conventional hematoxylin-eosin-saron staining followed by light microscope examination.
Abbreviations
The abbreviations used are: AP1, activating protein 1; ASV17, avian sarcoma virus 17; CEF, chicken embryo ®broblast; SPARC, secreted protein, acidic and rich in cysteine.
